Thanks guys. Lazy of me I know, but I was doing other things.An...

First 45 Last

Share
Profile

Follow
kickit2me

13,625 Posts.

4845

02/03/21

13:32

Post #: 51451605
Share

Originally posted by Quiltman: ↑

Yes, it is the ATCOR Pulse :

Our launch date for the Pulse remains on track and we’ve already received the first prototypes and test
units in our US and Sydney offices. Our first contracted order of the Pulse will be ~10,000 units. As a
guide to the impact of this new device on the revenues for the Company, our current device sales of
the XCEL central blood pressure monitor (which constitutes the most significant portion of our sales)
are in the low hundreds annually

A reminder from the ASX release about Andon and Atcor Pulse :

The first device under the Agreement to be named ATCOR “Pulse” (the Device) and will be
targeted for commercial launch in the US, Europe, Australia and China in Q4 2021.

ATCOR “Pulse” will be the first new medical device for ATCOR since 2012 and represents a
game changing medical technology collaboration for home-use vital signs monitoring. This
unique device will be the world’s first cloud-connected home-use BP monitor to include
ATCOR’s SphygmoCor® technology and Arty™, ATCOR’s new cardiovascular vital signs and
telehealth platform (Arty™ being an anagram of “Heart” and “Artery”).

The Agreement with Andon in conjunction with the ATCOR “Pulse” device significantly
expands the commercial market opportunity for CardieX into the home consumer health
device market, which is estimated to be worth $US2.5B annually (Source: Fortune Business
Insight).

When paired with ATCOR’s Arty™ app, the Device will provide full remote patient monitoring
of a patient’s vital signs at home. The remote patient monitoring market is estimated to
reach $US43B by 2027 (Source: 2020 Research & Markets Report).

At launch, the device and will also be fully telehealth-enabled with video, chat, messaging,
customizable screens and full vital signs sharing features between clinician and patient when
paired with the Company’s Arty™ app. ATCOR Pulse will be the first blood pressure device
ever to feature customizable screens and vital signs modules when integrated with the
Company’s new Arty™ app.

Expand

Thanks guys. Lazy of me I know, but I was doing other things.

An announcement late this year of the Pulse Launch along with a confirmed order should move the SP significantly.

Of course the launch of the Mobvoi wearable six months earlier than that will already have the SP above where it is now.

Going to be a great year for Cardiex - meanwhile CC is whipping the Atcor division to increase their revenues as well

...

CDX Price at posting: 8.3¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

What's causing the cost-of-living crisis, and how to navigate it